 Immune checkpoint inhibitor, ICI, therapies have been shown to be effective in treating cancer, however, they may also increase the risk of contracting nontubaculous mycobacterial, NTM, infections. Seven studies were identified that reported cases of NTM infections in patients undergoing ICI therapy. The majority of these cases involved mycobacterium avium complex bacteria, typically occurring one year or more after the initiation of ICI therapy. These infections do not appear to be associated with other immunosuppressive treatments. This article was offered by Andrea Lombardi, Andrea Gramegna, Margarita Ori, and others.